News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COCP chart
[-chart]finviz.com/chart.ashx?t=COCP&ty=c&ta=1&p=d&s=l[/chart]
[-chart]www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-replication-and-protease-inhibitor[/chart]
https://www.cocrystalpharma.com/development-pipeline/overview
NOTICE FATFINGER FIRST COUPE DAYS OF MAY,2021 [-chart]finviz.com/chart.ashx?t=COCP&ty=c&ta=1&p=d&s=l[/chart]
|
Followers
|
103
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3011
|
|
Created
|
09/05/13
|
Type
|
Free
|
| Moderators | |||
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses,
influenza viruses, and noroviruses.. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated
in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and
collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the
treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program
to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.
Our proprietary structural biology, enzymology and medicinal chemistry expertise enable us to develop novel antiviral agents.
These technologies and our market-focused approach to drug discovery are designed to effectively create small molecule therapeutics
that are safe, effective and convenient to administer.
Our technology provides a 3-D structure of inhibitor complexes at near-atomic resolution and immediate insight to guide SAR.
This helps us identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement.
For any given viral disease, there are different subtypes of viruses that cause the disease. For example, there are six different subtypes of virus that cause hepatitis C.
In hepatitis C, these subtypes are termed "genotypes." Each hepatitis C genotype is common in some parts of the world and rare in others.
Our technology allows us to develop drug candidates that are effective against all subtypes of a given virus. The drug candidate is called broad spectrum.
Viral resistance is a major obstacle to developing effective antiviral therapies that target viral molecules. Viruses reproduce rapidly and in enormous quantities.
During reproduction, random variations in viral molecules called mutations spontaneously develop. If such a mutation occurs in a viral molecule that is targeted
by an antiviral therapy that therapy may no longer be effective against the mutated virus. These mutated or "resistant viruses" can freely infect and multiply even
in individuals who have received treatment. In some cases, resistant virus strains may even predominate. For example, in the 2009 swine influenza pandemic,
the predominant strain was resistant to the best available therapies.
To overcome this obstacle, we identify and target critical components of viral replication enzymes that are crucial to the function of the enzyme and sensitive to change.
Any mutation in these critical enzyme components is likely to inactivate the enzyme and, in turn render the virus incapable of replicating. We test the effectiveness of
our compounds against potential viral mutations and select compounds with the highest barrier to resistance.
Patients at risk for suffering from many viral infections have few effective antiviral treatments from which to choose. Furthermore, some available treatment options have characteristics that limit their market potential. They are either priced too high, poorly tolerated, inconvenient to administer, ineffective against some viral subtypes or prone to emergence of resistance.
Our technology is based on the work of our Chief Scientist and Chairman of our Scientific Advisory Board, Dr. Roger Kornberg, and Dr. Raymond Schinazi.
Dr. Kornberg was awarded the 2006 Nobel Prize for Chemistry for his work to visualize a replication enzyme called RNA polymerase in action.
Using techniques called protein cocrystallization and X-ray crystallography, Dr. Kornberg and his colleagues generated three dimensional pictures
similar to the one on the left of RNA being transcribed by an RNA polymerase.
Dr. Schinazi is a world-class expert in discovering novel nucleoside therapeutics. He co-founded several successful antiviral companies including
Triangle Pharmaceuticals Inc., Idenix Pharmaceuticals Inc. and Pharmasset, Inc.
We are leveraging both Dr. Kornberg's and Dr. Schinazi's expertise in these methods to identify and develop new antiviral compounds.
Using these methods, our scientists are able to:
Influenza is a severe respiratory illness caused by either the influenza A or B virus that results in outbreaks of disease mainly during the winter months.
Currently approved antiviral treatments for influenza are partially effective and prone to viral resistance. Strains of flu virus that are resistant to approved treatments,
osteltamivir (Tamiflu™), zanamavir (Relenza™) and Xofluza have appeared and in some cases are predominant.
For example, the predominant strain of the 2009 swine influenza pandemic was resistant to Tamiflu™.
These drugs target one of two viral proteins, hemagglutinin or neuraminidase, neither of which is highly conserved between viral strains.
In fact, different influenza virus strains such as H1N1 and H5N1 are named by their respective differences in hemagglutinin (H) and neuraminidase (N) proteins.
The ability of the influenza virus to produce viable variants of these two proteins is the key to its ability to develop resistance.
To learn more about influenza, please visit the information page at the Center for Disease Control and Prevention (CDC).
References: https://www.cdc.gov/flu/
